Do you want to read an article? Please log in or register.
Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up
Type 2 Diabetes
COMMENTED
Related content
Type 2 DiabetesGlycemic Control
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Lancet Diabetes Endocrinol.
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group
doi: 10.1016/S2213-8587(17)
COMMENTED
Type 2 DiabetesGlycemic Control
Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes
Diabetes Care.
Yaron M, Roitman E, Aharon-Hananel G, Landau Z, Ganz T, Yanuv I, Rozenberg A, Karp M, Ish-Shalom M, Singer J, Wainstein J, Raz I
doi: 10.2337/dc18-0166.
Diabetes - GeneralType 2 Diabetes
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Lancet Diabetes Endocrinol.
Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A
doi: 10.1016/
Diabetes - GeneralType 2 DiabetesObesity and Bariatric Surgery
Clinical and Patient-Centered Outcomes in Obese Type 2 Diabetes Patients 3 Years After Randomization to Roux-en-Y Gastric Bypass Surgery Versus Intensive Lifestyle Management: The SLIMM-T2D Study
Diabetes Care.
Simonson DC, Halperin F, Foster K, Vernon A, Goldfine AB
doi: 10.2337/dc17-0487.
Type 2 DiabetesDiabetic ComplicationsGlycemic Control
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Diabetes Care.
Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group
doi: 10.2337/dc16-0024.
COMMENTED
Type 2 Diabetes
Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Griffin SJ, Rutten GEHM, Khunti K, Witte DR, Lauritzen T, Sharp SJ, Dalsgaard EM, Davies MJ, Irving GJ, Vos RC, Webb DR, Wareham NJ, Sandbæk A
doi: 10.1016/S2213-8587(19)30349-3.
COMMENTED
Type 2 Diabetes
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Lancet.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A
doi: 10.1016/S0140-6736(18)32260-8.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (the Diabetes & Aging Study)
Diabetes Care.
Vaisar T, Durbin-Johnson B, Whitlock K, Babenko I, Mehrotra R, Rocke DM, Afkarian M
doi: 10.2337/dc18-0699.
COMMENTED
Diabetes - General
Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus
Ann Intern Med.
Roglic G, Norris SL
doi: 10.7326/M18-1149.